Patent ID: 8481487

Claim:
A method for treating cancer overexpressing fibroblast growth factor 2 (FGF2) comprising administering to a subject with said cancer a therapeutically effective amount of a modified soluble FGF receptor Fc fusion comprising a fusion of a soluble FGF receptor 2 (sFGFR2) moiety with an Fc region of an immunoglobulin, wherein at least the 5 th N-glycosylation site of the FGFreeceptor moeity is occupied, and at most 45% of the N-glycans of the FGF receptor moiety have no sialyl group, wherein the FGF receptor Fc fusion binds FGF, and wherein the FGF receptor Fc fusion exhibits reduced aggregation or improved productivity relative to a soluble FGF receptor Fc fusion lacking the N-glycan at the 5th N-glycosylation site from the N-terminus.